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Available online 2 September 2016Background: Some risk classiﬁcations to determine prognosis of patients with non-muscle invasive bladder can-
cer (NMIBC) have disadvantages in the clinical setting. We investigated whether the EORTC (European Organi-
zation for Research and Treatment of Cancer) risk stratiﬁcation is useful to predict recurrence and progression
in Japanese patients with NMIBC. In addition, we developed and validated a novel, and simple risk classiﬁcation
of recurrence.
Methods: The analysis was based on 1085 patients with NMIBC at six hospitals. Excluding recurrent cases, we in-
cluded 856 patients with initial NMIBC for the analysis. The Kaplan–Meier method with the log-rank test were
used to calculate recurrence-free survival (RFS) rate and progression-free survival (PFS) rate according to the
EORTC risk classiﬁcations. We developed a novel risk classiﬁcation system for recurrence in NMIBC patients
using the independent recurrence prognostic factors based on Cox proportional hazards regression analysis. Ex-
ternal validation was done on an external data set of 641 patients from Kyorin University Hospital.
Findings: There were no signiﬁcant differences in RFS and PFS rates between the groups according to EORTC risk
classiﬁcation. We constructed a novel risk model predicting recurrence that classiﬁed patients into three groups
using four independent prognostic factors to predict tumour recurrence based on Cox proportional hazards re-
gression analysis. According to the novel recurrence risk classiﬁcation, there was a signiﬁcant difference in 5-
year RFS rate between the low (68.4%), intermediate (45.8%) and high (33.7%) risk groups (P b 0.001).
Interpretation: As the EORTC risk group stratiﬁcation may not be applicable to Asian patients with NMIBC, our
novel classiﬁcation model can be a simple and useful prognostic tool to stratify recurrence risk in patients with
NMIBC.
Funding: None.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Bladder cancer is the fourth most common malignancy in the West
(Jemal et al., 2010). In Asia, the incidence of bladder cancer is three toJuntendo University, Graduate
8421, Japan.
. This is an open access article underfour times less than Western countries (Ferlay et al., 2015). However,
population-based cancer registries covering 21% of the world's popula-
tion only included 8% of patients in these registries are from Asia
(Parkin, 2006). At initial diagnosis, about 85% of patients have non-mus-
cle-invasive bladder cancer (NMIBC), which is managed by transure-
thral resection of the bladder (TUR-Bt) with or without intravesical
therapy (Babjuk et al., 2013). Although the prognosis of NMIBC is gener-
ally favourable (survival rates at 5 years are above 80%), 50–80% ofthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2006; Fernandez-Gomez et al., 2009). Adequate risk classiﬁcation al-
lows clinicians to not only estimate the clinical behaviour of the tumour,
but also themagnitude of beneﬁt and the need for adjuvant therapy. Ac-
cordingly, some risk classiﬁcations that combine various parameters to
estimate the prognosis of NMIBC patients have been reported. There are
disadvantages in using these classiﬁcations in the clinical setting. For in-
stance, the EORTC(European Organization for Research and Treatment
of Cancer) risk table involve complex calculations and imbalance of
prevalence of individual risk groups (Sylvester et al., 2006). Further-
more, risk group stratiﬁcationwhich takes into account the riskwithout
Bacillus Calmette-Guerin (BCG) instillation or intravesical instillation of
chemotherapy has not been reported.
In the present study, we applied the EORTC risk group stratiﬁcation
to predict recurrence and progression in a Japanese cohort. In addition,
we developed a novel risk classiﬁcation of recurrence to easily estimate
a NMIBC patient's probability of recurrence after TUR-Bt based on a set
of routinely assessed clinical and pathological factors and validated this
novel classiﬁcation using another validation cohort.
2. Methods
2.1. Inclusion and Exclusion Criteria
In this multicentre retrospective cohort study, we analyzed data
from patients with NMIBC who underwent initial TUR-Bt at four
Juntendo University Hospitals and Teikyo University Hospital between
2000 and 2013 (JT cohort). To achieve adequate pathological staging,
the complete resection aimed to include themuscle layer of the bladder
wall. Randombiopsieswere taken fromnormal-appearingmucosal area
in patients with positive urine cytology and without abnormality of
upper and lower urothelial tract. Patients with any of the following
were excluded from the analysis: (i) non-urothelial carcinoma histolo-
gy, (ii) follow-up periods b3 months: (iii) history of muscle-invasive
or metastatic bladder cancer; (iv) history of carcinoma of the urethra,
prostate (ducts or stroma), or upper urinary tract; (v) history of local ra-
diation therapy to the pelvis; (vi) history of every kind of chemothera-
py; or (vii) history of previous BCG therapy. The TNM classiﬁcation
was assessed based on the 2002 TNM classiﬁcation of the International
Union Against Cancer (Sobin, 2002). The tumour grade was classiﬁed
according to the World Health Organization system (1973) (Mostoﬁ
et al., 1973). This study adhered to the Declaration of Helsinki.
The clinicopathological data, including age, sex, pathological T cate-
gory, pathological grade, tumour size, number of tumours, presence of
concomitant CIS, and intravesical therapywere obtained fromeach hos-
pital and merged. Each of these variables and their weight (score) ad-
hered to an EORTC scoring system (Sylvester et al., 2006).
Standard cystoscopy and urinary cytological examination, computed
tomography with contrast medium if possible, magnetic resonance
(MR) imaging and MR urography with contrast medium if possible,
were performed every three months for ﬁve years after TUR-Bt, and
subsequently every six months after ﬁve years. No patients had a ﬂuo-
rescence cystoscopy.
2.2. Recurrence-Free Survival (RFS), Progression-Free Survival (PFS) and
EORTC Risk Classiﬁcation
Visible recurrences or suspicious lesions were removed by TUR-Bt
and biopsy. All recurrences were conﬁrmed by histopathology, and pro-
gression was deﬁned as the development of muscle-invasive tumour or
metastatic disease. Progression was also regarded as recurrence. Pa-
tients without an event were censored at the last date of follow-up.
RFS and PFS were deﬁned as the period between the initial TUR-Bt
and recurrence or progression, respectively. Patients who died from
causes other than urothelial tumour were censored at the time of death.To evaluate the EORTC risk group stratiﬁcation for predicting recur-
rence and progression in JT cohort, a total recurrence score for each
patient was calculated based on the six clinicopathological factors
according to the EORTC scoring system for recurrence and progression
(Babjuk et al., 2008). Patients were then divided into four risk groups
for recurrence and progression (Sylvester et al., 2006; Babjuk et al.,
2008).
2.3. Recurrence Prognostic Factor Analysis and Novel Risk Classiﬁcation
Predicting Recurrence
Univariate and multivariate Cox proportional hazards regression
models were used to assess the impact of various clinicopathological
factors including age, sex, number of tumours, tumour size, pT, grade,
concurrent CIS, BCG instillation, and intravesical instillation of chemo-
therapy on time to recurrence in JT cohort.
We developed the novel risk classiﬁcation system for recurrence in
NMIBC patients using the independent recurrence prognostic factors
based on Cox proportional hazards regression analysis in the JT cohort.
Patients were subdivided into low, intermediate and high risk groups
according to their total score. Validation was done on an external data
set of 641 patients fromKyorin University Hospital. Inclusion and exclu-
sion criteria of the validation set were the same as the JT cohort.
2.4. Statistical Analysis
RFS rates were calculated by the Kaplan–Meier method and the dif-
ference between each groupwas evaluated using the log–rank test. Cal-
ibration of predictions on the novel risk score was evaluated by
comparing the predicted probability at 3 years with the Kaplan–Meier
survival probability using the training data (internal calibration). Simi-
lar analysis was performed using the external validation data (external
calibration). The performance of the predictions was assessed by plot-
ting actual survival against mean of the predicted risks. All statistical
analyses were performed using the JMP Pro-11® (SAS Institute Inc.,
Cary, NC, USA) and SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
P-values b0.05 were considered signiﬁcant and all reported P values
were two-sided. This study was conducted in accordance with ethical
principles of the Declaration of Helsinki. We registered this study in
UMIN clinical trial registry (UMIN000021878).
3. Results
3.1. Patient Characteristics in JT Cohort (Table 1)
This analysis was based on 1085 patients with NMIBC treated be-
tween 2000 and 2013 at the Juntendo and Teikyo University Hospitals.
Excluding recurrent cases, there were 856 patients with initial NMIBC
(male; n = 683, 79.8%, female; n = 173, 20.2%) in the JT cohort. The
baseline clinical and pathological characteristics of these patients are
presented in Table 1. All patients except one were Japanese. The non-
Japanese patient was a Caucasian. Median follow-up periods were
31 months (IQR: 15–48). Median age was 71 years old (IQR: 64–78).
A 2nd TUR was performed in 134 (15.7%) patients because of T1 or
high grade cancer. Based on this, 53 patients (39.6%) were diagnosed
with urothelial cancer. Immediate and adjuvant intravesical instillation
of chemotherapy were performed in 59 (6.9%) and 56 patients (6.5%),
respectively. Two hundred twenty (25.7%) patients were treated by
intravesical instillation of BCG. BCG maintenance therapy was per-
formed in only 21 patients (2.5%). According to the EORTC recurrence
risk classiﬁcation, the intermediate risk group had predominantly
higher number of patients (751; 87.8%) compared with the low (58;
6.7%) and high risk groups (47; 5.5%). In terms of EORTC progression
risk classiﬁcation, 191 (22.3%) patients were categorized as low-, 341
(39.8%) with intermediate-, and 324 (37.9%) high risk. Radical
cystectomy was performed in nine patients (1.1%). Four patients
Table 1
Patients and tumour characteristics in the JT cohort and the validation set.
JT set Validation set
Number of patients 856 641
Age, median (IQR) 71 (64–78) 72 (62–79)
Sex (%) Male 683 (79.8) 501 (78.2)
Female 173 (20.2) 140 (21.8)
pT classiﬁcation (%) pTa 522 (61.0) 433 (67.6)
pT1 289 (33.8) 201 (31.3)
pTis 45 (5.3) 7 (1.1)
Grade (%) G1 144 (16.8) 83 (12.9)
G2 513 (59.9) 386 (60.2)
G3 199 (23.2) 172 (26.8)
Tumour size (%) b10 mm 177 (20.7) 90 (14.0)
≥10 mm, b20 mm 283 (33.1) 251 (39.2)
≥20 mm 396 (46.3) 300 (46.8)
Number of tumours (%) 1 384 (44.9) 370 (57.8)
2, 3 266 (31.0) 35 (5.5)
≥4 206 (24.1) 236 (36.8)
Concomitant CIS (%) 109 (12.7) 35 (5.5)
2nd TUR-Bt (%) 134 (15.7) 39 (6.1)
BCG induction therapy (%) 220 (25.7) 92 (14.4)
Bladder instillation of chemotherapeutic agents (%) 111 (13.0) 137 (21.4)
EORTC recurrence risk classiﬁcation (%)
Low 58 (6.7) 49 (7.6)
Intermediate-low 437 (51.1) 305 (47.6)
Intermediate-high 314 (36.7) 194 (30.2)
High 47 (5.5) 93 (14.5)
EORTC progression risk classiﬁcation (%)
Low 191 (22.3) 215 (33.5)
Intermediate 341 (39.8) 216 (33.7)
High-low 243 (28.4) 154 (24.0)
High-high 81 (9.5) 56 (8.7)
Follow up period, median (IQR) 31 (15–48) 43 (17–73)
100 T. Ieda et al. / EBioMedicine 12 (2016) 98–104(0.5%) died of bladder cancer and one (0.1%) died of an unrelated
disease.
3.2. RFS Rates Stratiﬁed by the EORTC Recurrence Risk Classiﬁcation in JT
Cohort
During the observation period of this study, 342 of the 856 patients
(40.0%) experienced intravesical recurrence. Overall, RFS rates of these
patients were 60.3% at 2 years, 54.5% at 3 years, and 50.2% at 5 years.
The median time to recurrence was 63.0 months. The RFS rates at
5 years were 64.7% for the low risk group, 50.4% for the intermediate-
low risk group, 48.5% for the intermediate-high risk group and 44.1%a
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Fig. 1. a. Kaplan–Meier RFS curves, stratiﬁed by the EORTC recurrence risk classiﬁcation in JT coh
cohort, 2-, 3- and 5-year RFS rates of patients for each risk groupswere as follows, respectively;
risk; 59.4%, 54.5%, 48.5%, high risk; 58.0%, 50.4%, 44.1%. There were no signiﬁcant differences i
intermediate-low; P = 0.109, intermediate-low vs. intermediate-high; P = 0.511, interm
intermediate-high risk, orange: high risk. b. Kaplan–Meier PFS curves, stratiﬁed by the EORTC
patients in intermediate and high-low risk groups were statistically signiﬁcant (P b 0.001),
0.454), and high-low risk group vs high-high risk group (P= 0.338). In the JT cohort, 2-, 3- an
99.5%, 99.5%, 99.5%, intermediate risk: 98.5%, 98.5%, 98.5%, high-low risk: 91.3%, 89.6%, 86.3%,
risk, orange: high-high risk.for high risk group (Fig. 1a). There were no signiﬁcant differences in
RFS rates between groups according to the EORTC recurrence risk clas-
siﬁcation (low vs. intermediate-low; P = 0.109, intermediate-low vs.
intermediate-high; P= 0.511, intermediate-high vs. high; P= 0.707).
3.3. PFS Rates Stratiﬁed by the EORTC Progression Risk Classiﬁcation in JT
Cohort
Thirty-ﬁve (4.1%) patients had disease progression. Overall, PFS
rates of the 856 patients were 95.6% at 2 years, 95.0% at 3 years and
94.1% at 5 years. Median PFS rates were incomputable because of the
small number of patients with progression. The differences in PFS
rates between patients in intermediate and high-low risk group were
statistically signiﬁcant (P b 0.001). However, there were no signiﬁcant
difference for the low risk group vs intermediate risk (P= 0.454), and
high-low risk group vs high-high risk group (P= 0.338) (Fig. 1b).
3.4. Independent Prognostic Factors to Predict Tumour Recurrence After
TUR-Bt in JT Cohort
Univariate and multivariate Cox proportional hazards regression
analysis (Table 2) revealed that the number of tumours (P b 0.001), tu-
mour size (P= 0.003), BCG instillation (P b 0.001), and intravesical in-
stillation of chemotherapy (P=0.002) had signiﬁcant inﬂuence on time
to recurrence. Other clinical factors including age, sex, pT, grade, con-
comitant CIS were not statistically signiﬁcant prognostic factors for re-
currence. We could not make an analysis of progression because of the
incomputable median PFS.
3.5. A Novel Risk Classiﬁcation Predicting Recurrence After TUR-Bt in the JT
Cohort
We developed a novel risk classiﬁcation model for recurrence that
classiﬁed patients into three groups by usingweighted scores of clinico-
pathological factors identiﬁed by a univariate Cox proportional hazards
regression analysis (number of tumours, tumour size, BCG instillation
and intravesical instillation of chemotherapy) in the JT cohort. We
showed the 3-year recurrence probability in the JT and validation sets
in Table 3. The patients were then divided into three risk groups for re-
currence based on their total scores (low risk; total recurrence scores 0–
33, intermediate risk; total recurrence scores 34–44, high risk; total re-
currence scores 45–57). Calibration of the predictions was evaluated by
comparing the predicted probability at 3 years with the Kaplan–Meierb
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ort. There were no signiﬁcant differences in RFS rate between EORTC risk groups. In the JT
low risk: 70.0%, 64.7%, 64.7%, intermediate-low risk: 60.1%, 53.6%, 50.4%, intermediate-high
n RFS rates between groups according to the EORTC recurrence risk classiﬁcation (low vs.
ediate-high vs. high; P = 0.707). red: low risk, green: intermediate-low risk, blue:
progression risk classiﬁcation in JT cohort. Although the differences in PFS rates between
there were no signiﬁcant difference between low risk group vs intermediate risk (P =
d 5-year PFS rates of patients for each risk groups were as follows, respectively; low risk:
high-high risk: 86.3%, 86.3%, 86.3%. red: low risk, green: intermediate risk, blue: high-low
Table 2
Univariate and multivariate RFS rates according to clinicopathological risk factors.
Risk factor
Univariate Multivariate
Risk scoreRisk ratio 98% CI P Risk ratio 98% CI P
Age (b70 vs.) ≥71 1.05 0.85–1.29 0.671 0.96 0.78–1.19 0.720
Sex (female vs.) Male 1.10 0.83–1.44 0.524 1.07 0.93–1.42 0.622
Number of tumours (simple vs.) 2,3 1.19 0.93–1.53 0.160 1.46 1.14–1.89 0.003 8
≥4 1.39 1.06–1.81 0.016 1.93 1.46–2.55 b0.001 13
Tumour size (b1 cm vs.) ≥1 cm, b2 cm 1.28 0.93–1.79 0.132 1.24 0.89–1.76 0.204 4
≥2 cm 1.74 1.30–2.39 b0.001 1.77 1.30–2.47 b0.001 11
T stage (Ta vs.) T1 1.12 0.89–1.39 0.333 0.93 0.72–1.18 0.527
Concurrent CIS (no vs.) Yes 0.63 0.42–0.89 0.010 1.06 0.68–1.61 0.796
Grade (G1 vs.) G 2–3 1.11 0.84–1.48 0.470 1.03 0.77–1.40 0.840
BCG (yes vs.) No 2.38 1.80–3.22 b0.001 3.13 2.27–4.40 b0.001 22
Chemotherapy (yes vs.) No 1.36 0.99–1.92 0.058 1.67 1.21–2.36 0.001 11
101T. Ieda et al. / EBioMedicine 12 (2016) 98–104survival probability using the training data (internal calibration). The
predictions were assessed for calibration accuracy by plotting actual
survival against predicted risk (Fig. 2a). The predicted survival rate
from the risk score was well correlated with the actual observation of
5-year survival in the training data.
In this novel recurrence risk classiﬁcation, 280 cases (32.7%) were
classiﬁed as low risk, 344 (40.1%) as intermediate risk, and 232
(27.1%) as high risk. The RFS rates were 80.2% (at 2 years), 74.1% (at
3 years), 68.4% (at 5 years) for the low risk group; 54.8% (at 2 years),
49.5% (at 3 years), 45.8% (at 5 years) for intermediate risk; 42.1%, (at
2 years), 36.3% (at 3 years), 33.7% (at 5 years) for high risk. There
were signiﬁcant differences in 5-year RFS rates between low risk and in-
termediate risk (P b 0.001) and intermediate risk and high risk
(P b 0.001) (Fig. 3).
3.6. The External Validation of Our Novel Risk Classiﬁcation Predicting Re-
currence After TUR-Bt
We included 641 patients (male; n= 501, 78.2%, female; n= 140,
21.8%) who were treated at Kyorin University Hospital as external vali-
dation cohort. The baseline clinical and pathological characteristics of
the validation cohort are presented in Table 1. Although median age
(72 years: IQR 62–79, P = 0.735) and male-to-female ratio (78.2%,
P= 0.443) in the validation cohort were similar to the JT cohort, other
clinical background including pT (P b 0.001), tumour size (P= 0.001),
number of tumours (P b 0.001) and pathological characteristics such
as grade (P = 0.024) and concomitant CIS (P b 0.001) were distinctly
different from the JT cohort. In addition, there were fewer 2nd TUR
(P b 0.001) and BCG induction therapy (P b 0.001) in the validation co-
hort. On the other hand, adjuvant intravesical instillation of chemother-
apy (P b 0.001) was more frequent in the validation cohort. Radical
cystectomy was performed in 43 patients (6.7%). Twenty patients
(3.1%) died of cancer and 13 patients (2.0%) died of unrelated disease.
Overall, RFS rates of the 641 patients in the validation cohort wereTable 3
3-year recurrence probability in the JT set.
Total score 3-year recurrence probability
0 8.4%
5 10.7%
10 13.5%
15 17.0%
20 21.3%
25 26.5%
30 32.6%
35 39.8%
40 47.9%
45 56.7%
50 65.8%
55 74.8%
60 83.0%61.1% (at 2 years), 56.2% (at 3 years), and 50.2% (at 5 years). The PFS
rates for these patients were 91.7% (at 2 years), 91.0% (at 3 years),
89.1% (at 5 years). Although the PFS rate in the validation cohort was
signiﬁcantly lower than the JT cohort (P b 0.001), there were no signif-
icant differences in the RFS rate between the groups (P= 0.907).
According to this novel recurrence-risk classiﬁcation, 202 cases
(31.5%), 159 cases (24.8%) and 280 cases (43.7%) in the validation co-
hortwere classiﬁed into low, intermediate, and high risk groups, respec-
tively. There were signiﬁcant differences in the 5-year RFS rates
between the low risk group and intermediate risk group (P = 0.017)
and between the intermediate risk and high risk groups (P b 0.001;
Fig. 4).
We also evaluated the calibration by comparing the predicted prob-
ability at 3 years with the Kaplan–Meier survival probability using the
external validation data (external calibration). Using the validation
data set, the predictions were assessed for calibration accuracy by plot-
ting actual survival against predicted risk (Fig. 2b). The predicted sur-
vival rate from the risk score was reasonably well correlated with the
actual observation of 3-year survival in the external validation data set.
4. Discussion
Although EAU guideline on NMIBC appears to be a useful decision-
making clinical tool,(Ehdaie et al., 2013) one of the issues in the
EORTC risk table is the disproportion in prevalence. In this study,
87.8% of all patients (751 patients)were classiﬁed into the intermediate
risk group according to EORTC recurrence risk classiﬁcation in the JT co-
hort. Xu et al. (2013) and Sakano et al. (2011) showed similar results
with 78.0% and 92.5% of patients classiﬁed as intermediate risk, respec-
tively. The low frequency of low risk patients could possibly depend in
part to the lower rate of G1 tumours in the present study (18.5%) com-
paredwith the EORTC trials (43.2%) (Sylvester et al., 2006; Sakano et al.,
2011). Because other Asian studies have also reported lower rates of G1
tumours (Sakano et al., 2011; Kikuchi et al., 2009; Hong et al., 2008),
there might be racial difference in grade distribution of bladder cancer
between Asian and Caucasian populations, similar to the difference be-
tween Caucasians and African-Americans (Underwood et al., 2006).
Although some earlier studies reported signiﬁcant differences in RFS
and PFS rates between risk groups (Xu et al., 2013; Altieri et al., 2012;
Van Rhijn et al., 2010), other studies including ours (Fig. 1), found that
prediction of both recurrence and progressionwere poorly discriminat-
ed by the EORTC tables (Xu et al., 2013; Xylinas et al., 2013; Seo et al.,
2010; Fernandez-Gomez et al., 2011; Pillai et al., 2011). Also in another
Japanese cohort study (Sakano et al., 2011), no signiﬁcant differences in
the RFS rates were found between low risk and intermediate-low risk
groups or between intermediate-high risk and high risk groups. Regard-
ing PFS rates, we could ﬁnd no signiﬁcant differences between low risk
and intermediate risk (P=0.454) and high-low risk and high-high risk
(P=0.338). We stress that our patient population differed signiﬁcantly
from the population analyzed by the EORTC risk group (Sylvester et al.,
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Fig. 2. a. Internal validation b. External validation Calibration of risk score for 3-year survival in the internal and external validation data set. The predicted survival rate from the risk score
waswell correlatedwith the actual observation. The blue line indicates the ideal reference linewhere the predictedprobabilitiesmatch the observed proportions. The dashes represent the
nomogram-predicted probabilities grouped for each of the four quartile groups, along with the respective 95% conﬁdence intervals.
102 T. Ieda et al. / EBioMedicine 12 (2016) 98–1042006) in terms of geographic location, ethnic background, treatment al-
gorithm and malignant potential. These differences may explain why
EORTC table does not work well in Asian populations. These results un-
derline the need for improving current predictive tools (Xylinas et al.,
2013) among Asians.
In the EORTC series, only 171 patients (6.5%) were treated with BCG.
Subsequently the Spanish Urological Club for Oncological Treatment
(CUETO) developed a scoring model that predicted disease recurrence
and progression in 1062 patients with NMIBC treated with BCG from
four CUETO trials (Fernandez-Gomez et al., 2009). Although both the
EORTC risk tables (Sakano et al., 2011; Seo et al., 2010;
Fernandez-Gomez et al., 2011; Pillai et al., 2011; Kamat et al., 2007)
and the CUETO scoring model (Xylinas et al., 2013) (Pillai et al., 2011)
were externally validated and recommended by international guide-
lines (Babjuk et al., 2013; Burger et al., 2013), (Xylinas et al. (2013), re-
ported that disease recurrence and progression in NMIBC patients were
poorly discriminated by bothmodels. At present, the standard adjuvantPr
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Fig. 3. Kaplan–Meier recurrence curves in the JT cohort according to the novel recurrence
risk classiﬁcation There were signiﬁcant differences in RFS rates between low risk and
intermediate risk groups (P b 0.001) and between intermediate and high risk groups
(P b 0.001). The 2-, 3- and 5-year RFS rates of patients for each risk groups were as
follows, respectively; low risk: 80.2%, 74.1%, 68.4%, intermediate risk: 54.8%, 49.5%,
45.8%, high risk; 42.1%, 36.3%, 33.7% red: low risk, green: intermediate risk, blue: high risk.therapy in patients with NMIBC is the bladder instillation of BCG or che-
motherapy. Therefore, it is very important for patients and physician to
decide whether or not to receive the adjuvant instillation therapy. The
EORTC risk table is, however, of little use for deciding this.
We originally developed the novel risk classiﬁcation to predict re-
currence and progression for Japanese patients with NMIBC to compen-
sate for the shortcomings of the EORTC risk classiﬁcation. We
demonstrated clear and signiﬁcant differences in RFS rates between
the groups (P b 0.001; Fig. 3). In addition, unlike in EORTC risk classiﬁ-
cations, each risk group had almost equal proportion of patients. This
three-tiered risk group stratiﬁcation made it possible to determine re-
currence risk and choose the better adjuvant treatment for individual
Japanese patients. In addition, we performed the external validation
study to conﬁrm the usefulness of this novel recurrence-risk group
stratiﬁcation in Japanese patients. Even though there were clear differ-
ences in clinicopathological backgrounds between the original cohortPr
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Fig. 4.Kaplan–Meier recurrence curves of patients from the validation set according to the
novel recurrence classiﬁcation Therewere signiﬁcant differences inRFS rates between low
risk and intermediate risk groups (P = 0.017) and between intermediate and high risk
groups (P b 0.001). The 2-, 3- and 5-year RFS rates of patients for each risk groups were
as follows, respectively; low risk: 74.5%, 69.0%, 62.9%, intermediate risk: 66.2%, 61.1%,
57.1%, high risk; 47.1%, 43.0%, 34.6% red; low risk, green; intermediate risk, blue; high risk.
103T. Ieda et al. / EBioMedicine 12 (2016) 98–104and the validation set (Table 1), we found an even distribution of pa-
tients and signiﬁcant differences between groups (Fig. 4).
In addition, the scoring items of this novel risk classiﬁcation system
do not include pathological factors such as pathological T classiﬁcation,
concurrent CIS and malignant grade because multivariate analysis
showed no signiﬁcant differences. Therefore, theoretically, we could
use this classiﬁcation before TUR-Bt to predict prognosis. Furthermore,
in contrast to the existing risk classiﬁcations, this novel risk classiﬁca-
tion system is characterized by the scoring items including adjuvant
bladder instillation therapy of BCG and chemotherapeutic drugs on
the ﬁrst time. At present, the adjuvant therapy for NMIBC is almost
BCG instillation or intravesical instillation of chemotherapy and many
guidelines recommended these therapies. As a matter of course, this
novel classiﬁcation is not a tool to determine the indication for adjuvant
bladder instillation therapy. However, using this novel classiﬁcation we
can evaluate the recurrence-risk classiﬁcationwith orwithout these ad-
juvant intravesical instillation therapies.
The limitation of this study is that itwas a retrospective analysis. Par-
ticularly, our patient cohort included patients treated from 2000 to
2013, which was before immediate post-resection intravesical chemo-
therapy (Perlis et al., 2013) and maintenance intravesical therapy
(Martínez-Piñeiro et al., 2015) were widely-accepted practices in
Japan. Immediate intravesical instillation of chemotherapy and BCG
maintenance intravesical therapy were performed in just 236 (21.8%)
and 33 patients (3.0%), respectively. Also, only 140 (12.9%) patients
have had a 2nd TUR performed. Therefore, when BCG and 2nd TUR be-
come widely accepted in Asia as standard therapy, clinical outcome
could be different from this present study. Additional factors not includ-
ed in the EORTC model or in our novel classiﬁcation such as smoking
(Shiels et al., 2014; Burki, 2014), micropapillary histology ﬁnding, and
the depth of invasion (T1b/c) into lamina propria (Martin-Doyle et al.,
2015) could be added to a prognostic model to enhance its usefulness
in Asia. Furthermore, in this Japanese study, overall 4.1% patients had
disease progression. Compared with 10.7% in EORTC study (Sylvester
et al., 2006), this rate is obviously low. In this Japanese cohort, the rate
of G1 bladder cancer in JT set (16.8%) and in validation set (12.9%) are
clearly lower compared with EORTC study set (43.2%) (Sylvester et al.,
2006). Adversely, the rate of G3 bladder cancer in JT set (23.2%) and in
validation set (26.8%) are clearly higher compared with EORTC study
set (10.4%) (Sylvester et al., 2006). In spite of the high-rate of high-
grade NMIBC, in this Japanese study, we can see the very low number
of progression compared with Caucasian study. We can't deny the pos-
sibility that bladder cancer in Asian people might be of quite different
biology in contrast towestern cohorts. Therefore,we require the greater
consideration the usefulness of our novel classiﬁcation for Caucasian
NMIBC patients.
In conclusion, the number of tumours, tumour size, BCG instillation,
and intravesical instillation of chemotherapywere found to be indepen-
dent predictors for time to recurrence after TUR-Bt in Japanese patients
with NMIBC. Our novel, simple, and prognostic classiﬁcation may not
only predict the recurrence risk but greatly help to identify indicators
for adjuvant intravesical therapy. Given the fact that comparing with
advanced bladder cancer, NMIBC has only a small breakthrough drug
(Brower, 2015), further studies with a more patients in a more diversi-
ﬁed cohort are required to validate this risk classiﬁcation and to en-
hance the effectiveness of existing treatment for Asian patients with
bladder cancer.
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